# A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

> **NCT06094725** · PHASE1 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Relacorilant

## Key facts

- **NCT ID:** NCT06094725
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-06
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094725, "A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06094725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*